Delcath Systems, Inc. Announces Adjournment of Annual Meeting Meeting Scheduled to Reconvene on June 16
June 05 2017 - 5:15PM
Delcath Systems, Inc. (NASDAQ:DCTH) (the “Company”) announced today
that its 2017 Annual Meeting of Stockholders (the “Annual
Meeting”), scheduled for June 5, 2017, was convened and adjourned,
without any business being conducted. The Annual Meeting has been
adjourned until Friday, June 16, 2017 to allow more opportunity for
stockholders to vote on all proposals described in the Company’s
definitive proxy statement filed with the Securities and Exchange
Commission on May 5, 2017, including a proposal to approve an
amendment to its amended and restated certificate of incorporation
to effect a reverse stock split of its common stock, which the
Company believes is vitally important to the Company’s future.
The record date for the Annual Meeting remains
April 17, 2017. Stockholders who have previously submitted their
proxy or otherwise voted and who do not want to change their vote
need not take any action. Company stockholders as of the April 17,
2017 record date can vote, even if they have subsequently sold
their shares. The Company’s board of directors and management
respectfully request all such holders as of the record date to
please vote your proxies as soon as possible.
No changes have been made in the proposals to be
voted on by stockholders at the Annual Meeting. THE COMPANY
STRONGLY ADVISES ALL OF ITS STOCKHOLDERS TO READ THE PROXY
STATEMENT AND OTHER PROXY MATERIALS RELATING TO THE ANNUAL MEETING
BECAUSE THEY CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS
ARE AVAILABLE AT NO CHARGE ON THE SECURITIES AND EXCHANGE
COMMISSION'S WEBSITE AT WWW.SEC.GOV. In addition, copies of the
Proxy Statement and other documents may be obtained free of charge
by accessing the Company’s website at www.delcath.com or by
contacting the Company’s Corporate Secretary at 212-489-2100 or by
mail to Corporate Secretary, Delcath Systems, Inc., 1633 Broadway,
Suite 22C, New York, New York 10019.
Voting Instructions
All stockholders as of the April 17, 2017 record
date can vote, even if they have subsequently sold their shares,
and the Company encourages stockholders to do so before June 15,
2017 at 11:59 p.m. Eastern Time. Stockholders are reminded that
their vote is extremely important and are urged to complete, sign,
date and mail the proxy card at their earliest convenience. Any
stockholder who would like to vote by telephone may call
877-777-8133.
YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE
TODAY!
About Delcath Systems
Delcath Systems, Inc. is an interventional
oncology Company focused on the treatment of primary and metastatic
liver cancers. Our investigational product—Melphalan Hydrochloride
for Injection for use with the Delcath Hepatic Delivery System
(Melphalan/HDS) —is designed to administer high-dose chemotherapy
to the liver while controlling systemic exposure and associated
side effects. We have commenced a global Phase 3 FOCUS clinical
trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and
plan to initiate a Registration trial for intrahepatic
cholangiocarcinoma (ICC) in the Fall of 2017. Melphalan/HDS has not
been approved by the U.S. Food & Drug Administration (FDA) for
sale in the U.S. In Europe, our system has been commercially
available since 2012 under the trade name Delcath Hepatic CHEMOSAT®
Delivery System for Melphalan (CHEMOSAT), where it has been used at
major medical centers to treat a wide range of cancers of the
liver.
Forward Looking Statements:
Private Securities Litigation Reform Act of 1995
provides a safe harbor for forward-looking statements made by the
Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to:
the timing and results of the Company’s clinical trials
including without limitation the OM and ICC clinical trial
programs, timely enrollment and treatment of patients in the
global Phase 3 OM clinical trial, IRB or ethics committee clearance
of the Phase 3 OM and ICC Registration trial protocols
from participating sites and the timing of site activation
and subject enrollment in each trial, the impact of the
presentations at major medical conferences and future clinical
results consistent with the data presented, approval of Individual
Funding Requests for reimbursement of the CHEMOSAT procedure, the
impact, if any of ZE reimbursement on potential CHEMOSAT
product use and sales in Germany, clinical adoption, use and
resulting sales, if any, for the CHEMOSAT system to deliver and
filter melphalan in Europe including the key markets of Germany and
the UK, the Company’s ability to successfully commercialize the
Melphalan HDS/CHEMOSAT system and the potential of the Melphalan
HDS/CHEMOSAT system as a treatment for patients with primary and
metastatic disease in the liver, our ability to obtain
reimbursement for the CHEMOSAT system in various markets,, approval
of the current or future Melphalan HDS/CHEMOSAT system for delivery
and filtration of melphalan or other chemotherapeutic agents for
various indications in the U.S. and/or in foreign markets, actions
by the FDA or other foreign regulatory agencies, the Company’s
ability to successfully enter into strategic partnership and
distribution arrangements in foreign markets and the timing and
revenue, if any, of the same, uncertainties relating to the timing
and results of research and development projects, our ability to
maintain NASDAQ listing, and uncertainties regarding the Company’s
ability to obtain financial and other resources for any research,
development, clinical trials and commercialization activities.
These factors, and others, are discussed from time to time in our
filings with the Securities and Exchange Commission. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date they are made. We undertake no obligation
to publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are
made.
Contact Information:
David Boral
Managing Director
CoreIR
Tel: 516 222 2560
Email: davidb@coreir.com